Ki20227

CAS No. 623142-96-1

Ki20227( Ki 20227 | Ki-20227 )

Catalog No. M15358 CAS No. 623142-96-1

A potent, selective, orally active c-Fms inhibitor with IC50 of 2 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 50 In Stock
5MG 87 In Stock
10MG 147 In Stock
25MG 284 In Stock
50MG 507 In Stock
100MG 707 In Stock
500MG 1431 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Ki20227
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, selective, orally active c-Fms inhibitor with IC50 of 2 nM.
  • Description
    A potent, selective, orally active c-Fms inhibitor with IC50 of 2 nM; weakly inhibits KDR, c-Kit, and PDGFRβ with IC50 of 12, 451, and 217 nM, respectively, no activty against Flt-3, c-Src, Fyn, EGFR, FGFR2, Met, Btk, PKA, and PKCα (IC50>1,000 nM); inhibits the M-CSF-dependent cell growth, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
  • In Vitro
    Ki20227 (0.1-1000 nM; 72 hours) with 100 and 1,000 nM almost suppresses M-NFS-60 cell growth and HUVEC cell growth, respectively. Ki20227 (0.1-1000 nM; 1 hour) suppresses M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner. Cell Viability Assay Cell Line:M-NFS-60 cells, HUVEC cells, human A375 melanoma cells Concentration:0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM Incubation Time:72 hours Result:100 and 1,000 nM almost suppressed M-NFS-60 cell growth and HUVEC cell growth, respectively.Cell Viability Assay Cell Line:RAW264.7 cell lysate Concentration:0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM Incubation Time:1 hourResult:Suppressed M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner.
  • In Vivo
    Ki20227 (orally;10-50 mg/kg/d for 20 days) of 50 mg/kg/d of Ki20227 for 20 days markedly decreases the osteolytic lesion areas. ki20227 during global ischemia led to a significant deficit in microglial density in the CNS in mice, and CSF1R-inhibition led to a significant reduction in the neuronal density of mice. Animal Model:4-week-old male F344/NJcl-rnu rats.Dosage:10, 20, and 50 mg/kg Administration:Orally; once per day for 20 days Result:Oral administration of 50 mg/kg/d markedly decreased the osteolytic lesion areas.
  • Synonyms
    Ki 20227 | Ki-20227
  • Pathway
    Tyrosine Kinase
  • Target
    CSF1R
  • Recptor
    CSF-1R,VEGFR2
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    623142-96-1
  • Formula Weight
    480.5362
  • Molecular Formula
    C24H24N4O5S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 7.2 mg/mL
  • SMILES
    O=C(NC(C1=NC=CS1)C)NC2=CC=C(OC3=CC=NC4=CC(OC)=C(OC)C=C34)C=C2OC
  • Chemical Name
    Urea, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ohno H, et al. Mol Cancer Ther. 2006 Nov;5(11):2634-43. 2. Ohno H, et al. Eur J Immunol. 2008 Jan;38(1):283-91. 3. Uemura Y, et al. J Neuroimmunol. 2008 Mar;195(1-2):73-80.
molnova catalog
related products
  • JNJ-28312141

    JNJ-28312141 is a potent, orally active CSF-1 receptor (CSF-1R) kinase inhibitor with IC50 of 0.69 nM.

  • Vimseltinib

    DCC-3014 is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM) extracted from the patent WO2014145025A2 (Example 10).

  • Chiauranib

    Chiauranib is a multi-target inhibitor against tumor angiogenesis and exhibits potent anticancer effects.